Key points from article :
ImmuneAGE Bio, a company specializing in immune system rejuvenation, has received $50,000 in funding from the VitaDAO community, with almost unanimous backing in a vote by the community members.
The company is focusing on immune aging, which is associated with age-related diseases such as cardiovascular disease, neurodegeneration, and cancer, and has been highlighted as a critical health factor during the COVID-19 pandemic.
The firm's unique screening platform rapidly identifies new candidates for pre-clinical trials.
ImmuneAGE's lead compound, IA101, is a non-toxic small molecule that targets hematopoietic stem cells (HSCs) in the bone marrow with the aim of rejuvenating them to extend healthspan and lifespan.
IA101, which has already shown efficacy and safety in multiple human trials, is being developed with the funding to create new analogs, enhance potency, identify molecular targets, and strengthen the compound's intellectual property.
A team of experts at VitaDao, who reviewed the ImmuneAGE Bio proposal, highlighted the company as the first longevity biotech focusing solely on immune aging drug discovery and noted IA101's promising in vivo proof of concept data.
VitaDao noted that while the company has considerable experience and has already shown promising results, the research is still in early stages and is not without risks, including the unknown target of IA101 and potential financing risks if market conditions weaken.
